Screener
Capricor Therapeutics CAPR Receivable from credits from ARPA
Receivable from credits from ARPA at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GrantsReceivableCurrent.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | March 31, 2026 / (unaudited) | December 31, 2025 | December 31, 2025 |
|---|---|---|---|
| CURRENT ASSETS | |||
| Cash and cash equivalents | $105,421,484 | $ | $287,847,312 |
| Marketable securities | 173,188,430 | 30,281,603 | |
| Receivables | — | 59,167 | |
| Prepaid expenses and other current assets | 4,478,895 | 4,751,674 | |
| TOTAL CURRENT ASSETS | 283,088,809 | 322,939,756 | |
| PROPERTY AND EQUIPMENT, net | 28,502,617 | 18,312,238 | |
| OTHER ASSETS |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's receivable from credits from ARPA?
- Capricor Therapeutics (CAPR) reported receivable from credits from ARPA of $0 in Q1 2026.
- How has Capricor Therapeutics's receivable from credits from ARPA changed year-over-year?
- Capricor Therapeutics's receivable from credits from ARPA decreased by 100.0% year-over-year, from $59.83K to $0.
- What does receivable from credits from ARPA mean?
- This metric represents the current portion of funds due to the company from government agencies or public institutions under research and development grant agreements. It reflects the value of services performed or milestones achieved for which payment has been earned but not yet received. This asset is critical for assessing the company's short-term liquidity and the reliability of its non-dilutive funding sources.
Ask your AI about Capricor Therapeutics's receivable from credits from arpa.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude